Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24309370

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 Jan
First author
Kubota K

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jan;15(1):13-4. doi: 10.1016/S1470-2045(13)70555-2.
    note
    Source null
    related pmid
    24309369
    relationship
    Comment in

Authors and identifiers

  1. name
    Kubota K
    type
    Author
  2. name
    Hida T
    type
    Author
  3. name
    Ishikura S
    type
    Author
  4. name
    Mizusawa J
    type
    Author
  5. name
    Nishio M
    type
    Author
  6. name
    Kawahara M
    type
    Author
  7. name
    Yokoyama A
    type
    Author
  8. name
    Imamura F
    type
    Author
  9. name
    Takeda K
    type
    Author
  10. name
    Negoro S
    type
    Author
  11. name
    Harada M
    type
    Author
  12. name
    Okamoto H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kubota K
    type
    Author
  2. name
    Hida T
    type
    Author
  3. name
    Ishikura S
    type
    Author
  4. name
    Mizusawa J
    type
    Author
  5. name
    Nishio M
    type
    Author
  6. name
    Kawahara M
    type
    Author
  7. name
    Yokoyama A
    type
    Author
  8. name
    Imamura F
    type
    Author
  9. name
    Takeda K
    type
    Author
  10. name
    Negoro S
    type
    Author
  11. name
    Harada M
    type
    Author
  12. name
    Okamoto H
    type
    Author
bibliography ids
  1. nci-bib-3fb64f46c32b3ecd7afee7ef
book metadata
content sha256
505426c2841a63e5ec058f8e09bab0b35e59302cb837512a9c547d41e3a707d5
document type
citation
dois
  1. 10.1016/S1470-2045(13)70511-4
electronic publication date
display
2013 Dec 3
precision
day
year
2013
evidence scope
bibliographic_metadata_only
id
pubmed:24309370
immutable id
pubmed:24309370@505426c2841a63e5ec058f8e09bab0b35e59302cb837512a9c547d41e3a707d5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
106-13
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Jan;15(1):13-4. doi: 10.1016/S1470-2045(13)70555-2.
    note
    Source null
    related pmid
    24309369
    relationship
    Comment in
outcomes validated
false
pmid
24309370
provenance
batch id
af10498814d931b53231
provider
NCBI PubMed ESummary
record sha256
6f5c009a7a13dabc79f9b526b003182e6ba58dc1083cb331990201d0ee296843
response sha256
077a09272afe77e74d5ff01cb33335ddb8a638b7afbafb70ec20e837a0c85c7f
retrieved at
2026-09-09T23:47:00.193465+00:00
publication date
display
2014 Jan
precision
month
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24309370/
title
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

Preserved source evidence · Not medical advice